Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Total Liabilities (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Total Liabilities readings, the most recent being $5.8 million for Q1 2026.

  • Quarterly Total Liabilities rose 19.87% to $5.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Mar 2026, up 19.87% year-over-year, with the annual reading at $5.3 million for FY2025, 6.52% down from the prior year.
  • Total Liabilities hit $5.8 million in Q1 2026 for DiaMedica Therapeutics, up from $5.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $5.8 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
  • Average Total Liabilities over 5 years is $3.6 million, with a median of $3.2 million recorded in 2023.
  • The largest annual shift saw Total Liabilities soared 121.41% in 2023 before it decreased 8.89% in 2024.
  • DiaMedica Therapeutics' Total Liabilities stood at $2.6 million in 2022, then rose by 20.83% to $3.1 million in 2023, then skyrocketed by 81.34% to $5.6 million in 2024, then fell by 6.52% to $5.3 million in 2025, then rose by 11.12% to $5.8 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Total Liabilities are $5.8 million (Q1 2026), $5.3 million (Q4 2025), and $5.4 million (Q3 2025).